| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
| Targets |
6-Hydroxyindole is an endogenous potent and long-lasting inhibitor of the organic anion transporting polypeptide 1B1 (OATP1B1) with an IC₅₀ of approximately 10 µM in cell-free assays. OATP1B1 is a hepatic uptake transporter involved in the disposition of many drugs and endogenous compounds. The compound also inhibits human tyrosinase with an IC₅₀ of 20 µM.
|
|---|---|
| ln Vitro |
In vitro, 6-hydroxyindole is used as a biochemical reagent and research tool. It serves as a long-lasting inhibitor of OATP1B1 and is used to study transporter-mediated drug uptake. The compound shows potent inhibition of human tyrosinase, making it useful for studying melanin biosynthesis. It is also a reactant for the asymmetric synthesis of notoamide J and for preparing indole oxyacetic acid derivatives as PPAR agonists.
|
| ln Vivo |
In vivo data for 6-hydroxyindole as a therapeutic agent are limited. As an endogenous OATP1B1 inhibitor, it may play a role in modulating drug disposition in vivo. The compound is elevated in the plasma of renal failure patients, suggesting a potential role as a biomarker. Specific in vivo pharmacokinetic and pharmacodynamic data are not well-documented.
|
| Enzyme Assay |
For in vitro transporter inhibition assays, 6-hydroxyindole is evaluated for OATP1B1 inhibitory activity. Standard protocols involve using OATP1B1-overexpressing cells or membrane vesicles and measuring the uptake of a fluorescent or radiolabeled substrate (e.g., estradiol-17β-glucuronide) in the presence of the compound. IC₅₀ values are calculated from dose-response curves. The compound shows an IC₅₀ of approximately 10 µM.
|
| Cell Assay |
For in vitro cell-based experiments, 6-hydroxyindole is evaluated for tyrosinase inhibitory activity. Tyrosinase enzyme assays are performed using L-DOPA or tyrosine as substrate, and the production of dopachrome is monitored spectrophotometrically at 475 nm. The compound shows an IC₅₀ of 20 µM against human tyrosinase. The compound can also be used in melanocyte cell culture studies to assess effects on melanin production.
|
| Animal Protocol |
In vivo animal studies for 6-hydroxyindole are limited. The compound may be used in pharmacokinetic studies to assess its effects on OATP1B1-mediated drug disposition. Standard in vivo protocols involve administration to rodents via oral gavage or intravenous injection, with measurement of plasma concentrations of OATP1B1 substrates. Specific protocols for this compound are not well-documented.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
6-Hydroxyindole is a known human indole metabolite. Pharmacokinetic properties of 6-hydroxyindole are not extensively characterized. The compound has a molecular weight of 133.15 g/mol, which is favorable for oral bioavailability. As an endogenous compound, it is likely subject to metabolic conjugation (e.g., glucuronidation, sulfation) and renal excretion. The compound is elevated in the plasma of renal failure patients, suggesting renal clearance is a major elimination pathway. |
| Toxicity/Toxicokinetics |
Toxicity Summary
It is safe at the current usage and concentration. Ingredient, concentration, and usage information can be found at: https://cir-reports.cir-safety.org 6-Hydroxyindole is a research chemical and should be handled with appropriate laboratory safety precautions. As an indole derivative, it may cause skin and eye irritation. The compound is for research use only and not for human therapeutic or diagnostic applications. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment and working in a fume hood. |
| References | |
| Additional Infomation |
Structure in the first source
6-Hydroxyindole (1H-indol-6-ol, CAS 2380-86-1) is primarily a research-grade biochemical reagent, not an FDA-approved pharmaceutical drug. Its primary applications are as an endogenous OATP1B1 inhibitor for transporter studies and as a tyrosinase inhibitor for melanin biosynthesis research. The compound is also used as a reactant in organic synthesis. No clinical trials or approved indications exist for this compound. |
| Molecular Formula |
C8H7NO
|
|---|---|
| Molecular Weight |
133.15
|
| Exact Mass |
133.052
|
| CAS # |
2380-86-1
|
| PubChem CID |
524508
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
343.2±15.0 °C at 760 mmHg
|
| Melting Point |
124-130 °C
|
| Flash Point |
161.4±20.4 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.739
|
| LogP |
1.41
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
10
|
| Complexity |
126
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC2=C1C=CN2)O
|
| InChi Key |
XAWPKHNOFIWWNZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H7NO/c10-7-2-1-6-3-4-9-8(6)5-7/h1-5,9-10H
|
| Chemical Name |
1H-indol-6-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (751.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (18.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (18.78 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (18.78 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.5103 mL | 37.5516 mL | 75.1033 mL | |
| 5 mM | 1.5021 mL | 7.5103 mL | 15.0207 mL | |
| 10 mM | 0.7510 mL | 3.7552 mL | 7.5103 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
